Tirzepatide Before and After: Real Results for UAE Users (2026)
By Amir Arsalan | Updated March 2026 | Backed by SURMOUNT clinical trial data
- SURMOUNT-1 trial: average 20.9% body weight loss at 72 weeks on the 15 mg dose
- Real-world data: 16.5% average loss at 1 year (slightly lower than trials)
- Head-to-head vs semaglutide (JAMA 2025): 20% vs 14% at ~18 months
- Meaningful results usually visible by month 3; peak results at 9-12 months
- Results depend heavily on dose, diet, exercise, and consistency
If you are searching for tirzepatide before and after results, you are probably at the point where the numbers matter — not the marketing. This guide breaks down exactly what the clinical trials showed, what real-world users experience month by month, and the honest factors that separate big results from modest ones. Whether you are starting at 90 kg or 130 kg, you will find realistic benchmarks here grounded in data from the SURMOUNT program.
For context on how tirzepatide works and how to get started, see our tirzepatide complete guide for the UAE.
What the SURMOUNT Trials Actually Showed
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind approved for weight management. The SURMOUNT clinical trial program is the largest body of evidence for its before-and-after results.
In SURMOUNT-2, which enrolled participants with type 2 diabetes, weight loss was clinically meaningful but somewhat lower than SURMOUNT-1, consistent with the known effect of diabetes on GLP-1 responsiveness.
A 3-year extension of SURMOUNT-1, presented at the European Congress on Obesity (ECO) in 2025, confirmed that weight loss is sustained for at least 3 years in people who continue treatment. One high-responder subgroup (predominantly female, no obesity complications) achieved an average of 31% total body weight loss at 3 years.
In June 2025, a direct head-to-head phase 3b trial published in JAMA confirmed tirzepatide outperforms semaglutide 2.4 mg: 20% loss vs 14% at approximately 18 months. See our tirzepatide vs Ozempic comparison for a full breakdown.
Real-World Before and After: Lower, But Still Impressive
Clinical trials select motivated participants in controlled conditions. Real-world data tells a more honest story — and it is still impressive.
A large real-world study published in PMC (2025) followed patients treated with tirzepatide in clinical practice. At 1 year, average weight loss was -16.5% (-17.2 kg), compared to -14.1% for semaglutide users. Importantly, only 25.9% of real-world users reached the maximum 15 mg dose — those who did lost significantly more.
Cleveland Clinic research (2025) confirmed: participants who stayed on high-dose tirzepatide lost an average of 18.0%, versus 3.6% for those who discontinued early. Adherence is the single biggest predictor of your before-and-after outcome.
Week-by-Week and Month-by-Month Results Timeline
Understanding the timeline matters as much as the end result. Tirzepatide is not a fast drug — it is a slow, cumulative process. Here is what the data and clinical experience show at each stage.
| Timeframe | What to Expect | Avg. Weight Lost |
|---|---|---|
| Week 1–2 | Reduced appetite and cravings. Little to no scale change. Some nausea possible. | 0–1 kg |
| Week 3–4 | Appetite clearly suppressed. Smaller meal portions feel satisfying. Scale starts moving. | 1–3 kg total |
| Month 2–3 | Noticeable weight change. Clothes fitting differently. Dose may be titrated up. | 4–7 kg total |
| Month 4–6 | Most active fat-loss phase. Energy improving. Before/after photos now clearly show change. | 8–14 kg total |
| Month 7–9 | Continued strong loss. Most users approach or reach target dose (15 mg). | 12–18 kg total |
| Month 10–12 | Loss rate slows as a new metabolic set point is approached. Plateau possible. | 15–22 kg total |
| Year 2–3 | Maintenance or continued slow loss. 3-year extension showed results sustained. | Up to 31% (high responders) |
For a more granular breakdown of the timeline, see our dedicated tirzepatide weight loss results timeline article.
Before and After by Starting Weight: What to Expect
One of the most common questions is: "How many kilograms will I lose?" The answer depends heavily on your starting weight. Percentage-based losses translate to very different kilogram amounts.
Heavier starting weights produce larger absolute losses in kilograms, even at similar percentage outcomes. This is why tirzepatide is particularly impactful for those with significant obesity — a 130 kg person losing 20.9% loses over 27 kg, a transformation that is visible and felt in every aspect of daily life.
Factors That Affect Your Before and After Results
Two people on the same dose will not get the same result. Here are the variables that the data consistently shows matter most.
1. Dose Achieved
The SURMOUNT-1 data is unambiguous: higher dose = greater loss. The jump from 5 mg (15.0%) to 15 mg (20.9%) is nearly 6 percentage points. Proper titration — starting low and stepping up every 4 weeks — is essential. See our tirzepatide dosage guide for UAE for the full titration schedule.
2. Diabetes Status
People with type 2 diabetes consistently lose less weight on GLP-1-based therapies than those without. SURMOUNT-2 (diabetes population) showed lower percentage losses than SURMOUNT-1. This is a metabolic reality, not a failure of the drug.
3. Diet Quality
Tirzepatide powerfully reduces appetite, but it does not prevent eating calorie-dense foods. The best results come from pairing the reduced hunger signal with a structured, protein-rich diet. Users who eat 1.2–1.6 g of protein per kg of body weight preserve more muscle and lose more fat.
4. Physical Activity
Exercise amplifies results and, critically, helps preserve lean muscle mass during weight loss. Resistance training 2-3 times per week is strongly recommended alongside tirzepatide.
5. Adherence and Consistency
Cleveland Clinic data shows early discontinuers lost only 3.6% on average. Long-term continuers on high dose lost 18%. There is no substitute for staying on the medication and completing your dose titration.
6. Sex and Hormonal Status
The 3-year SURMOUNT extension found that a subgroup with predominantly female participants achieved the highest total losses (~31%). Hormonal factors influence response, though the exact mechanisms are still being studied.
Tirzepatide vs Semaglutide: Before and After Comparison
The head-to-head data is now definitive. A phase 3b trial published in JAMA in June 2025 (NCT05822830) compared tirzepatide directly against semaglutide 2.4 mg (Wegovy/Ozempic) in adults with obesity. Results at approximately 18 months:
Tirzepatide (Mounjaro)
- Average loss: 20% of body weight
- Real-world 1-year: ~16.5%
- Dual GIP + GLP-1 mechanism
- 3-year sustained efficacy confirmed
- Max dose: 15 mg/week
Semaglutide (Ozempic/Wegovy)
- Average loss: 14% of body weight
- Real-world 1-year: ~14.1%
- GLP-1 mechanism only
- Well-established long-term safety data
- Max dose: 2.4 mg/week
The verdict: tirzepatide produces approximately 6 percentage points more weight loss than semaglutide in head-to-head comparison. For a 100 kg person, that is the difference between losing 14 kg and losing 20 kg. For a full comparison, read our tirzepatide vs Ozempic guide.
Tips to Maximize Your Tirzepatide Before and After Results
Start at 2.5 mg and work up to 15 mg over 20 weeks. Do not rush — but do not stay at a lower dose longer than needed.
Aim for 1.4–1.6 g per kg body weight daily. Protein prevents muscle loss and keeps you full longer — essential when appetite is suppressed.
Use an app to track meals for awareness. Tirzepatide reduces hunger but not food quality — alcohol and ultra-processed foods still blunt results.
2–3 sessions per week of weight training preserves muscle mass and improves body composition beyond what the scale shows.
Consistency in timing maintains stable blood levels and maximises appetite suppression across the full 7-day cycle.
The first 8 weeks look modest on the scale. The appetite suppression is building. Dramatic before-and-after changes happen months 3–9.
Why Results Vary: The Honest Picture
Tirzepatide is the most effective approved weight-loss medication in history — and yet some people lose 10% while others lose 30%. This is not random. The key drivers of individual response include:
- Gut hormone receptor sensitivity — genetic variation in GIP and GLP-1 receptor expression affects how strongly the drug works at the cellular level.
- Baseline insulin resistance — more severe insulin resistance slightly blunts the GLP-1 component of the response.
- Gut microbiome composition — emerging research suggests microbiome diversity influences GLP-1 drug response, though this is not yet clinically actionable.
- Sleep quality — poor sleep elevates ghrelin (hunger hormone) and can partially counteract tirzepatide's appetite suppression.
- Stress and cortisol — chronic high cortisol promotes visceral fat storage and is a common reason for plateaus.
The realistic expectation for a motivated UAE user who completes dose titration, follows a protein-prioritising diet, and exercises consistently: 15–22% body weight loss over 12 months.
Will You Regain Weight After Stopping Tirzepatide?
This is the most important question that before-and-after photos rarely answer. The SURMOUNT-4 trial specifically studied what happens when tirzepatide is stopped after 36 weeks of treatment. The result: participants regained approximately two-thirds of their lost weight within 52 weeks of stopping.
This reflects the biological reality of obesity — it is a chronic condition driven by hormonal and neurological set points that tirzepatide works against, not cures. This does not diminish the drug's value, but it does mean that for most users, long-term or indefinite treatment is the most sustainable path to maintaining results.
Some people use tirzepatide as a "reset" — losing significant weight, building healthier habits, and then maintaining with lifestyle alone. This works for a meaningful minority, but the data suggests most people benefit from continuing treatment.
Frequently Asked Questions
Most users notice reduced appetite within the first 1–2 weeks. Visible scale movement (1–3 kg) typically appears by weeks 4–6. Meaningful before-and-after changes are usually clear by month 3, with the most dramatic transformation period being months 3 through 9.
In clinical trials, the average monthly weight loss ranges from 1.5 to 3 kg per month during the active loss phase (months 1–9). Real-world data shows slightly lower rates of around 1–2.5 kg per month. Individual results depend heavily on starting weight, dose titration, diet, and exercise habits.
The SURMOUNT-1 trial showed the 15 mg dose produced an average of 20.9% body weight loss at 72 weeks. Extension data at 3 years showed some subgroups achieving up to 31% total loss. In the JAMA head-to-head trial (2025), tirzepatide users averaged 20% weight loss at 18 months.
In a direct head-to-head phase 3b trial published in JAMA in 2025, tirzepatide produced 20% average weight loss vs 14% for semaglutide at approximately 18 months. Real-world data corroborates this: tirzepatide users lost 16.5% vs 14.1% for semaglutide at 1 year.
Yes. Mounjaro (tirzepatide) by Eli Lilly is available in the UAE. CoreSup stocks original Mounjaro KwikPens in 10 mg, 12.5 mg, and 15 mg doses for UAE delivery. Always consult a licensed healthcare provider before starting tirzepatide.
Yes. The SURMOUNT-4 trial showed that participants who stopped tirzepatide after 36 weeks regained approximately two-thirds of their lost weight within 52 weeks. Continuing the medication and maintaining lifestyle changes are key to sustaining results.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
